Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec and Cardiokine launch phase III heart drug trial

Biogen Idec and Cardiokine launch phase III heart drug trial

15th February 2008

Biogen Idec and Cardiokine have announced the launch of a phase III study investigating the use of lixivaptan for congestive heart failure patients who suffer from hyponatremia.

The trial will compare lixivaptan to placebo in 650 patients with hyponatremia – an electrolyte disturbance marked by low sodium levels in the blood.

Barry Ticho, vice-president of cardiology at Biogen Idec, expressed the company’s excitement over the initiation of phase III studies for lixivaptan.

“Lixivaptan has the potential to address significant unmet needs for heart failure patients as well as other clinical conditions associated with hyponatremia,” he said.

Cardiokine’s senior chief medical officer Cesare Orlandi confirmed the importance of the phase III trial, which was launched this week.

“This multi-national study utilises a novel design and addresses the needs of an important subset of the heart failure population,” he added.

The collaboration sees Biogen Idec responsible for lixivaptan’s global commercialisation while Cardiokine has the option for co-promotion in the US.

Earlier this month, Biogen Idec published its financial results for the 2007 fiscal year, with the company announcing an 18 per cent increase in revenues to $3.17 billion (1.63 billion pounds).

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.